The road to elimination of Hepatitis C: Analysis of SVR versus new HCV infections in 91 countries
|
|
- Lawrence Grant
- 5 years ago
- Views:
Transcription
1 tract #205 The road to elimination of Hepatitis C: Analysis of SVR versus new HCV infections in 91 countries Dr Andrew Hill, PhD, University of Liverpool, UK Sanjay Nath, Bryony Simmons MPH, Imperial College, London, UK
2 kground: WHO Targets O targets for elimination of Hepatitis C by 2030: 90% of people infected with HCV are diagnosed 80% of infected people are treated tabase: country-level rates of diagnosis, treatment in 2016 search question: are we on the road to elimination of HCV
3 hods: country-level database laris Observatory 2016: Total viraemic infections New HCV infections Numbers treated (assumed 90% SVR rate) Percentage of patients diagnosed, new diagnoses HCV related deaths (0.5% per year) Non-HCV related deaths (1.5% per year) For countries with missing data, regional averages were used.
4 hods: changes in prevalence ange in prevalence, : V infections in new HCV infections - cures - HCV-related deaths - non-hcv related deaths
5 hods: diagnosis and treatment HO targets
6 infections diagnosed by 2016 Foundation
7 ent new HCV diagnosis in 2016 oundation
8 diagnosis by Gross National Income WHO Target: 90% diagnosed High Income Upper-Middle Lower-middle Low income Countries Countries Countries Countries 44% 17% 15% 9% 3% 1.6% 1.3% 0.8% Foundation HIC UMIC LMIC LIC Income Group Diagnosis Rate 2016 New Diagnosis Rate 2016 Ref: Polaris databas
9 atients cured per new HCV infection: countries Foundation
10 ew HCV infections per patient cured: ountries Foundation
11 ges in HCV prevalence: Foundation
12 ges in HCV prevalence: Canada: -6% Russia: +4% USA: -9% Spain: -9% Egypt: -11% India: +1% China: -3% Japan: -13% Brazil: -4% Australia: -13% Foundation
13 ults: diagnostic burn-out Spain and Portugal could soon reach the stage where there are no more diagnosed patients availab t: stage, cure of HCV is limited by rates of new HCV diagnosis, which are currently low. ostic burn-out potential outcomes, based on 2016 data y HCV Diagnosed New HCV Cures Outcome Epidemic before 2016 Diagnoses in million 235,000 (13%) 10,000 (0.6%) 43,000 (2.4%) Dx Burn-out in , ,000 (43%) 5500 (1.7%) 25,000 (8%) Dx Burn-out in 202 al 96,000 37,000 (39%) 1300 (1.3%) 4400 (4.6%) Dx Burn-out in 202 Foundation
14 itations stimates of HCV prevalence and new infections are changing a ew data become available this analysis needs to be updated egularly. e cannot assume that current rates of diagnosis and treatment ill be maintained. Warehousing of patients may already have inished in some countries. Many patients could be diagnosed ith HCV, but unable to access or afford HCV DAAs.
15 clusions n 2016, there were 1.6 million people newly infected with HCV, versus 1 illion people cured. he worldwide HCV epidemic fell from 69.6 million in 2016 to 68.3 million n 2017 a reduction of only 2% his reduction is not large enough to achieve elimination of HCV by 2030 etween 6-7 million people need to be diagnosed and treated each year arm reduction needs to be intensified, to lower infection rates
16 es versus costs of HCV DAAs $160,000 $140,000 $120,000 $100,000 $80,000 $60,000 $40,000 $20,000 $142,710 $104,723 $96,404 $87,632 $84,281 $76,757 $68,280 $65,616 $50,059 $47,972 $37,729 $33,800 $29,361 $11,598 $9,906 $174 $0
17 real cost of HCV elimination F/DCV can now be produced for <$50 per 12-week treatment course $50 per course, it would cost $3.5 billion to treat all 70 million people cted with HCV worldwide bal sales of HCV DAAs from 1Q2014 to 2Q2017 average $1.6 billion r month. erefore, all 70 million people with HCV worldwide could be treate the equivalent of 10 weeks of commercial sales of the HCV DAA Gotham 2017, July 2017, International AIDS Society Conference, Paris, France
Generic HCV DAAs. Economics and sustainability. Dr. Andrew Hill Pharmacology and Therapeutics University of Liverpool, UK
Generic HCV DAAs Economics and sustainability Dr. Andrew Hill Pharmacology and Therapeutics University of Liverpool, UK Sunday, 23rd July 2017 Paris, France www.iasociety.org HCV DAAs can be made very
More informationAccess to hepatitis medicines
World Hepatitis Summit November 2 nd 2017 Access to hepatitis medicines Dr Andrew Hill, PhD, Department of Translational Medicine University of Liverpool, UK 1 Changes in HCV prevalence: 2016-2017 Worldwide,
More informationUniversal access to medicine: HIV and beyond
Universal access to medicine: HIV and beyond Dr Andrew Hill Department of Pharmacology and Therapeutics University of Liverpool United Kingdom UNAIDS STAC meeting, Lilongwe, May 15 th 2017 Universal access
More informationAASLD, Boston, USA, 10 th November 2014 [oral presentation]
Effects of Sustained Virological Response on the of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 34,563 patients with Hepatitis C infection. Andrew
More informationSetting the Stage Key Challenges in Elimination
Setting the Stage Key Challenges in Elimination Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto Disclosures Consulting: Abbvie, Contravir,
More informationWHO Strategy and Goals for Viral Hepatitis Elimination
WHO Strategy and Goals for Viral Hepatitis Elimination No Disclosures Outline 1. Global strategy for elimination WHO targets and rationale 2. The global response so far Gaps in achieving the HBV and HCV
More informationAn Introduction to Access to Diagnostics. 14:00-14:45 BST 17 June
An Introduction to Access to Diagnostics 14:00-14:45 BST 17 June Chair: Dr Greg Martin, Specialist Registrar, Public Health Medicine and Editor-in- Chief of Globalization and Health @drgregmartin Speakers:
More informationDiabetic Eye Care; Workforce Challenges and opportunities
Diabetic Eye Care; Workforce Challenges and opportunities Hugh R. Taylor, AC, MD April 2013 Bangkok How many ophthalmologists in practice and training worldwide? Study designed and conducted by ICO in
More informationFinancing the Response to HIV/AIDS in Low and Middle Income Countries: Funding for HIV/AIDS from the G7 and the European Commission
Financing the Response to HIV/AIDS in Low and Middle Income Countries: Funding for HIV/AIDS from the G7 and the European Commission Presented at: Post G8 Briefing: Future Financing To Address The Global
More informationSection 9: Tackling the Hepatitis C epidemic: a global landscape
Section 9: Tackling the Hepatitis C epidemic: a global landscape Céline Grillon (Médecins du Monde) Training Hepatitis C and HR for PWUD, 19 th -24 th Sept. 2016, Nairobi, Kenya Learning objective of the
More informationPortland Area Health Priorities
Portland Area Indian Health Service Portland Area Health Priorities CAPT Thomas Weiser, MD, MPH Medical Epidemiologist Portland Area Budget Formulation Meeting Portland, November 30, 2017 Overview Brief
More informationThe Global Picture in Blood Transfusions: A Quick Overview
The Global Picture in Blood Transfusions: A Quick Overview Jim MacPherson President & CEO MacPherson Strategies jim@macphersonstrategies.com +1 202 468 6548 24 March 2017 WHO 2016 Of the 113 million blood
More informationHomie Razavi. CDA Foundation Polaris Observatory. From Economic Analysis to Financial Dialogue
Homie Razavi CDA Foundation Polaris Observatory From Economic Analysis to Financial Dialogue The CDA Foundation Accelerate hepatitis B and C elimination through verified data, modeling, intervention strategies,
More informationProspective Urban Rural Epidemiologic ( PURE) Study.
Prospective Urban Rural Epidemiologic ( PURE) Study. 17 HIC, MIC and LIC countries, 628 urban and rural communities, 154,000 randomly selected, BP measured using an Omron with standard methods in 90%.
More informationJoint Programming in Neurodegenerative Disease Research (JPND)
Joint Programming in Neurodegenerative Disease Research (JPND) Building Alliances and Collaborations Prof. Philippe Amouyel, MD, PhD JPND Chair France Disclosure CEO of Fondation Plan Alzheimer Conference
More informationWe are seeking to supply governments and private parties with affordable versions of drugs to treat HCV.
March 18, 2015 Mr. Gregg Alton Executive Vice President, Corporate and Medical Affairs Gilead Sciences 333 Lakeside Drive Foster City, CA 94404 Via Email: gregg.alton@gilead.com Re: Request for license
More informationCYCLOTRONS WORLD MARKET REPORT & DIRECTORY EDITION TOC and Summary USED IN NUCLEAR MEDICINE MARKET DATA, COMPANIES PROFILES.
CYCLOTRONS USED IN NUCLEAR MEDICINE WORLD MARKET REPORT & DIRECTORY MARKET DATA, COMPANIES PROFILES TOC and Summary EDITION 2015 A report written by Paul-Emmanuel Goethals & Richard Zimmermann Page 1/5
More informationThe Global Impact of Dementia
The Global Impact of Dementia Martin Prince No conflicts of interest Centre for Global Mental Health Health Service and Population Research Department King s College London 1066drg@iop.kcl.ac.uk Agenda
More informationChronic hepatitis C Building access into drug development: DNDi strategy
Chronic hepatitis C Building access into drug development: DNDi strategy July 2017 IAS Isabelle Andrieux-Meyer Head of HIV/HCV Clinical Programs Declaration of interests Isabelle Andrieux-Meyer from Drugs
More informationA Summary of Childhood Cancer Statistics in Australia,
What is the Australian Paediatric Cancer Registry (APCR)? The APCR is one of only a few national registries of childhood cancer in the world. It covers all Australian children aged 0-14 years old at diagnosis.
More informationInfectious Diseases. Colin R. Howard ( 郝高林 ) Royal Veterinary College University of London ( 伦敦大学皇家兽医学院 )
Infectious Diseases Colin R. Howard ( 郝高林 ) Royal Veterinary College University of London ( 伦敦大学皇家兽医学院 ) The Challenge of Infectious Disease Infectious disease represents the greatest challenge to mankind
More informationFunding Universal Access through a Global Health Charge on alcohol and tobacco: feasibility in the 20 countries with the largest HIV epidemics
Funding Universal Access through a Global Health Charge on alcohol and tobacco: feasibility in the 20 countries with the largest HIV epidemics Dr Andrew Hill, Pharmacology and Therapeutics, Liverpool University,
More informationISAPS International Survey on Aesthetic/Cosmetic Procedures Performed in 2010
ISAPS International Survey on Aesthetic/Cosmetic Procedures Performed in 2010 Methodology: Survey participants completed a two page, English based questionnaire that focused on the number of surgical and
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationTreatment and Access to Drugs
Treatment and Access to Drugs Presenter: Co-leads: Peter Beyer & Philippa Easterbrook WHO Regional Advisor for South East Asia (SEARO): Razia Narayan Pendse Session Objectives By the end of this session,
More informationIDENTIFYING KEY CONSUMER TRENDS IN WEIGHT MANAGEMENT EWA HUDSON GLOBAL HEAD OF HEALTH AND WELLNESS RESEARCH FOOD MATTERS LIVE, NOVEMBER 2014
IDENTIFYING KEY CONSUMER TRENDS IN WEIGHT MANAGEMENT EWA HUDSON GLOBAL HEAD OF HEALTH AND WELLNESS RESEARCH FOOD MATTERS LIVE, NOVEMBER 2014 2 CONSUMER ATTITUDES TOWARDS WEIGHT LOSS AND OBESITY PERFORMANCE
More information7/30/2017. One World Medical Physics: Challenges and Opportunities in Cancer Care. Worldwide Demographic Shift
People 60 Years and Older ( in Millions) 7/30/2017 One World Medical Physics: Challenges and Opportunities in Cancer Care Jatinder R Palta PhD, FAAPM, FASTRO, FACR Virginia Commonwealth University, and
More informationSchedules and strategies for HPV immunization Conclusions and proposed recommendations for SAGE
1 Schedules and strategies for HPV immunization Conclusions and proposed recommendations for SAGE Andrew Pollard, SAGE Member SAGE meeting, 18 20 October 2016 Questions for SAGE 2 1. What is the incremental
More informationAccess to treatment and disease burden
Access to treatment and disease burden Robert Flisiak Department of Infectious Diseases and Hepatology Medical University in Białystok, Poland Moulin de Vernègues, 27-29 August 2015 Disclosures Advisor
More informationTHE MEDICINES PATENT POOL APPROACH TO SCALE UP ACCESS TO HIV AND HCV TREATMENT. Esteban Burrone Head of Policy
THE MEDICINES PATENT POOL APPROACH TO SCALE UP ACCESS TO HIV AND HCV TREATMENT Esteban Burrone Head of Policy LEARNING FROM THE HIV RESPONSE EVOLUTION OF AIDS DRUG PRICES: 2000-2008 Source: MSF (2008)
More informationClusters in Sports Industry: EU Approach and Support
Enterprise and Industry José Freitas Policy Officer SMEs: Clusters and Emerging Industries unit Clusters in Sports Industry: EU Approach and Support EPSI Conference on Sports and Innovation June 13 th,
More informationSummary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Phase III, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen
More informationACCESS AND IMPLEMENTATION OF IFN-FREE THERAPY IN PEOPLE WHO INJECT DRUGS : WHERE TO FROM HERE FOR LOW AND MIDDLE INCOME COUNTRIES
ACCESS AND IMPLEMENTATION OF IFN-FREE THERAPY IN PEOPLE WHO INJECT DRUGS : WHERE TO FROM HERE FOR LOW AND MIDDLE INCOME COUNTRIES Niklas Luhmann Médecins du Monde 09 October 2015 International Symposium
More informationCotton Trade 02/03 03/04 04/05 05/06 06/07 07/08 08/09 09/10 10/11 11/12 12/13
Cotton Trade Net Exporters Africa Argentina Australia India Other Former Soviet Union Other Latin America Other Middle East Pakistan Turkey United States Uzbekistan Total Net Exports 5.01 5.62 5.62 5.66
More informationRaising Tobacco Taxes A Summary of Evidence from the NCI-WHO Monograph on the Economics of Tobacco and Tobacco Control
Raising Tobacco Taxes A Summary of Evidence from the NCI-WHO Monograph on the Economics of Tobacco and Tobacco Control Jeremias N. Paul Jr. Coordinator, Tobacco Control Economics (TCE) Prevention of Noncommunicable
More informationMore information at
Report Information More information at https://www.htfmarketreport.com/reports/1288313 Global Homeopathic Products Market Professional Survey Report 2018 Report Code: HTF1288313 Pages: 111 Price: 1-User
More informationTreatment Gaps and Barriers to control of Hypertension
Treatment Gaps and Barriers to control of Hypertension Dr Clara Chow The George Institute, University of Sydney PHRI, McMaster University Affiliated with the University of Sydney Dr Chow is supported by
More informationHealth for Humanity 2020 Goals 2
2017 for Humanity Report Better for Humanity 2020 s 2 At Johnson & Johnson, we aspire to profoundly change the trajectory of health for humanity. Our for Humanity 2020 s, underpinned by 16 targets, focus
More informationEpidemiology and Priority Actions for Curing HCV and Treating Chronic HBV
Epidemiology and Priority Actions for Curing HCV and Treating Chronic HBV Dr. Marc Bulterys Monday 27 th March 2017 MPP meeting at InterCon Hotel Overview of Presentation Hepatitis global elimination strategy
More informationMonitoring EU Agri-Food Trade: Development until May 2018
Monitoring EU Agri-Food Trade: Development until May 2018 May 2018: Agri-food exports and trade surplus keep at record levels The monthly values of EU agri-food trade in May 2018, compared to April, remained
More informationGlobal Best Practices in Tobacco Control
Global Best Practices in Tobacco Control Samira Asma, DDS, MPH Chief, Global Tobacco Control Centers for Disease Control and Prevention Regional Consultation on Multisectoral Policies for Prevention and
More informationDiagnosis and monitoring of hepatitis C (HCV) in Morocco Current Status and strategies for universal access
Diagnosis and monitoring of hepatitis C (HCV) in Morocco Current Status and strategies for universal access Benchmarking HCV diagnostics, fibrosis evaluation, and treatment monitoring Pauline Londeix,
More informationBACKGROUND AND RATIONALE
ULTRA RARE DISEASE EXAMPLE: SURVIVAL IN PATIENTS WITH NIEMANN PICK-C DISEASE Daniel Rosenberg, PhD Head of Epidemiology BACKGROUND AND RATIONALE Niemann Pick Type-C (NP-C) disease is an ultra rare condition
More informationThe Global Tobacco Problem
Best Practices in Tobacco Control Policy: An Update Johanna Birckmayer, PhD, MPH Campaign for Tobacco Free Kids The Global Tobacco Problem Almost one billion men and 250 million women are daily smokers
More informationTobacco Insights May
Tobacco Insights 2015 - May Product Code: TI0017MR Published Date: June 2015 Report Price: US$ 150 (Single Copy) Synopsis Tobacco Insights 2015 - May report is a qualitative report providing extensive
More informationCan we afford DAA for all???
The 4P Group Public Health Community Physicians and scientists Policy makers Pharmaceutical companies Can we afford DAA for all??? Maud Lemoine Imperial College London MRC, the Gambia Unit, West Africa
More informationNon communicable Diseases
Non communicable Diseases Vision, Goals and Challenges Where we are in Palestine? Dr. Johny R. Khoury Consultant Cardiologist Medical Relief Prevention and Diagnostic Center of cardiovascular diseases
More informationGlobal HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( )
Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) By Region- North America, Europe, APAC and RoW By Country - United
More informationFinancing the Response to AIDS in Low- and Middle- Income Countries: International Assistance from Donor Governments in 2010
Financing the Response to AIDS in Low- and Middle- Income Countries: International Assistance from Donor Governments in 2010 Authors: Jennifer Kates (Kaiser Family Foundation), Adam Wexler (Kaiser Family
More informationREFERENCE CODE GDHCER022 PUBLICAT ION DATE AUGUST 2013 OVERWEIGHT AND OBESITY - EPIDEMIOLOGY FORECAST TO 2022
REFERENCE CODE GDHCER022 PUBLICAT ION DATE AUGUST 2013 OVERWEIGHT AND OBESITY - Executive Summary Obesity is an escalating global public health problem that has reached pandemic proportions. It is caused
More informationWELLNESS COACHING. Wellness & Personal Fitness Solution Providers
WELLNESS COACHING Wellness & Personal Fitness Solution Providers Introducing Ourselves... We are Personal Wellness Coaches 2 We help people look and feel better by: - Educating on proper nutrition (80%)
More informationREFERENCE CODE GDHCER043 PUBLICAT ION DATE NOVEMBER 2013 PARKINSON S DISEASE - EPIDEMIOLOGY FORECAST TO 2022
REFERENCE CODE GDHCER043 PUBLICAT ION DATE NOVEMBER 2013 Executive Summary Parkinson s disease is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer s
More informationHCV epidemiology: Access to treatment and care on a global level Margaret Hellard
HCV epidemiology: Access to treatment and care on a global level Margaret Hellard Burnet Institute, Melbourne Disclosures I receive fellowship support from the National Health and Medical Research Council
More informationType 1 Diabetes Australian Research Impact Analysis
Type 1 Diabetes Australian Research Impact Analysis Executive Overview Summary Type 1 diabetes research in Australia Australia is making a significant contribution to the quantity and quality of the global
More informationSofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4
Phase 3 Treatment Experienced Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4 Bourlière M, et al. N Engl J Med. 217;376:2134-46. POLARIS-4: Study Features POLARIS-4 Trial Design:
More informationRobert Burton. Globalization of Cancer and the Challenge of Improving Cancer Cure and Care in Developing Countries EQUATOR. Monash University.
Globalization of Cancer and the Challenge of Improving Cancer Cure and Care in Developing Countries Robert Burton Monash University 33 0 SYDNEY PERTH EQUATOR SkinCan AD145 A New Platform To join forces
More informationUpdate on HCV Treatment
Update on HCV Treatment Ajay Bharti, MD Associate Professor of Medicine Division of Infectious Diseases University of California San Diego 2018 April 28, 2018 Clinically relevant questions in HCV-HIV coinfected
More informationFinancing the Response to AIDS in Low- and Middle- Income Countries: International Assistance from Donor Governments in 2011
Financing the Response to AIDS in Low- and Middle- Income Countries: International Assistance from Donor Governments in 2011 Authors: Jennifer Kates (Kaiser Family Foundation), Adam Wexler (Kaiser Family
More informationHepatitis C. Graciela Diap X Congress of the SEMTSI Bilbao, 23 October 2017
Hepatitis C Graciela Diap X Congress of the SEMTSI Bilbao, 23 October 2017 Source: Polaris Observatory An estimated 70 million individuals are infected with HCV (viremic), a prevalence of ~1% in 2016 Prevalence
More informationGraham Cooke. Imperial College & Imperial College NHS Trust. NIHR Research Professor. BHIVA meeting October 2018
Graham Cooke Imperial College & Imperial College NHS Trust NIHR Research Professor BHIVA meeting October 2018 @grahamscooke The Big Picture Scaling up the global response The role of microelimination The
More informationGLOBAL HIV STATISTICS
F A C T S H E E T W O R L D A I D S D A Y 2017 GLOBAL HIV STATISTICS 20.9 million people were accessing antiretroviral therapy in June 2017. 36.7 million [30.8 million 42.9 million] people globally were
More informationProgrammatic management of LTBI : a two pronged approach for ending the TB epidemic. Haileyesus Getahun Global TB Programme WHO/HQ
Programmatic management of LTBI : a two pronged approach for ending the TB epidemic Haileyesus Getahun Global TB Programme WHO/HQ What is latent TB infection? A state of persistent immune response to stimulation
More informationSofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) Forecast and Market Analysis to GDHC1150DFR / Published May 2013
Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) Forecast and Market Analysis to 2022 GDHC1150DFR / Published May 2013 Executive Summary Sofosbuvir and Sofosbuvir/Ledipasvir: Key Metrics in Nine
More informationThe Global Burden of Viral Hepatitis
The Global Burden of Viral Hepatitis Benjamin Cowie WHO Collaborating Centre for Viral Hepatitis Victorian Infectious Diseases Reference Laboratory Doherty Institute, University of Melbourne benjamin.cowie@mh.org.au
More informationIMPACT OF HPV IMMUNIZATION STRATEGIES & POTENTIAL FOR CERVICAL CANCER ELIMINATION
IMPACT OF HPV IMMUNIZATION STRATEGIES & POTENTIAL FOR CERVICAL CANCER ELIMINATION Marc Brisson Full Professor Université Laval, Canada SAGE meeting October 24, 2018 Geneva 1 Questions A. What is the potential
More informationQ3WORLDWIDE GAME ON PERFORMANCE REPORT. KELLER WILLIAMS WORLDWIDE PERFORMANCE REPORT THIRD QUARTER 2018 KW Turkey
Q3WORLDWIDE PERFORMANCE REPORT GAME ON KW Turkey OUR STORY Keller Williams is more than a real estate company. From its inception, we were designed to be a positive yet disruptive force whose mission is
More informationEssential Oil & Aromatherapy Market Research Report- Forecast to 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/3319 Essential Oil & Aromatherapy Market Research Report- Forecast to 2023 Report / Search Code: MRFR/F-B & N/2386-HCRR
More informationSession 17 Practical Implementation of New Technologies in Low-to-Middle Income Countries
17 Practical Implementation of New Technologies in LMICs Session 17 Practical Implementation of New Technologies in Low-to-Middle Income Countries Introduction Jacob (Jake) VanDyk Western University London,
More informationKey Highlights continued
Financing the Response to AIDS in Low- and Middle- Income Countries: International Assistance from the G8, European Commission and Other Donor Governments in 2009 Authors: Jennifer Kates (Kaiser Family
More informationREFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Gardasil: Key Metrics in Nine Major
More informationJournals of Brazil -Overview
Journals of Brazil -Overview Abel L. Packer SciELO - FAPESP/ PROGRAM, Director Federal University of São Paulo Foundation, Advisor 1st Brazil-China Bilateral Meeting on STM Publishing São Paulo, 23 May
More informationAuthors: Jennifer Kates (Kaiser Family Foundation), José-Antonio Izazola (UNAIDS), Eric Lief (CSIS).
Financing the response to AIDS in low- and middleincome countries: International assistance from the G8, European Commission and other donor Governments, 2006 Authors: Jennifer Kates (Kaiser Family Foundation),
More informationTHE Price of a Pandemic 2017
THE Price of a Pandemic 2017 From 2000-2015: 33 million people died because of TB at a global economic cost of $617bn This report was produced the Global TB Caucus, an international network of over 2,000
More informationMolecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research
Molecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research " Projected to grow at a CAGR of almost 9% from 2016 to 2024, the molecular diagnostics market
More informationSIGN UP TODAY ENTRY FEE: PRIZE: ORGANISER:
SIGN UP TODAY ENTRY FEE: PRIZE: ORGANISER: Argentina Australia Belgium Brazil Columbia Costa Rica Croatia Denmark Egypt England France Germany Iceland Iran Japan Mexico Morocco Nigeria Panama Peru Poland
More informationInfectious Disease Testing. ULTRA Product Line. Safety is not a Matter of Chance
Infectious Disease Testing ULTRA Product Line Safety is not a Matter of Chance ULTRA Product Line The best answer for HBV, HCV and HIV screening: a global automated solution for safe results. Monolisa
More informationSimplified HCV Diagnostics
Simplified HCV Diagnostics Viral Hepatitis Elimination Meeting Amsterdam 2016 Dr Dmytro Donchuk HIV, TB and Viral Hepatitis Adviser For Dr Teri Roberts Diagnostic Adviser MSF SAMU and Access Campaign Speaker
More informationGlobal review of the challenges in use of traditional medicine and WHO perspective
Global review of the challenges in use of traditional medicine and WHO perspective Dr Xiaorui Zhang Coordinator Traditional Medicine Department of Technical Cooperation for Essential Drugs and Traditional
More informationEnriched RWE study in the Nordics a case study
Enriched RWE study in the Nordics a case study RWD conf. Helsinki, November 28, 2018 Susanne Kihlblom, MSc Pharm., Diplom.Clin.Trials Copyright 2017 IQVIA. All rights reserved. IQVIA 2017. All rights reserved.
More informationLifting The Burden. WHO s Global Campaign to Reduce the Burden of Headache Worldwide. TJ Steiner
Lifting The Burden WHO s Global Campaign to Reduce the Burden of Headache Worldwide TJ Steiner Division of Neuroscience and Mental Health Imperial College London 04/03/09 TJ Steiner 1 The argument (as
More informationGlobal Cosmetic Dentistry Market Research Report 2018
Report Information More information from: https://www.wiseguyreports.com/reports/3029111-global-cosmetic-dentistry-market-research-report- 2018 Global Cosmetic Dentistry Market Research Report 2018 Report
More informationNew Diagnostic Methods for Hepatitis C
New Diagnostic Methods for Hepatitis C Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationNoronet report, April 2014
Noronet report, April 2014 Janko van Beek, Annelies Kroneman, Harry Vennema, Marion Koopmans A. van Leeuwenhoeklaan 9 3721 MA Bilthoven Postbus 1 3720 BA Bilthoven www.rivm.nl T 030 274 91 11 F 030 274
More informationHepatitis C Elimination: Australia s progress
Hepatitis C Elimination: Australia s progress Margaret Hellard Burnet Institute, Melbourne Disclosures I receive fellowship support from the National Health and Medical Research Council (Australia). The
More informationJohn Amis/AP Images for AIDS. Healthcare Foundation
John Amis/AP Images for AIDS Healthcare Foundation Sofosbuvir Bought in 2011 by Gilead for 11 billion: "a huge and risky bet on the next generation of hepatitis C treatments" (Reuters) Patent situation:
More informationPegIntron (Hepatitis C Virus) Forecast and Market Analysis to GDHC1143DFR / Published May 2013
PegIntron (Hepatitis C Virus) Forecast and Market Analysis to 2022 GDHC1143DFR / Published May 2013 Executive Summary PegIntron (peginterferon alfa-2b) Key Metrics in the Major Pharmaceutical Markets 2012
More informationShort Range Outlook for Steel Demand Autumn OECD Steel Committee, Paris, 10 December Short Range Outlook overview
Short Range Outlook for Steel Demand Autumn 29 OECD Steel Committee, Paris, 1 December 29 Content Short Range Outlook overview Background of the Forecast Regional overviews Conclusion 2 1 Short Range Outlook
More informationAuthors: Jennifer Kates (Kaiser Family Foundation), Eric Lief (The Stimson Center), Carlos Avila (UNAIDS).
Financing the response to AIDS in low- and middleincome countries: International assistance from the G8, European Commission and other donor Governments in 2008 Authors: Jennifer Kates (Kaiser Family Foundation),
More informationProgramme of Action for Cancer Therapy PACT. PROGRAMME OF ACTION FOR CANCER THERAPY
Programme of Action for Cancer Therapy PACT pact@iaea.org http://cancer.iaea.org PROGRAMME OF ACTION FOR CANCER THERAPY Since 1980 the IAEA has invested US $202 million to establish safe and effective
More informationCall to Action. Global and Regional Hepatitis Action Plans: Opportunities and considerations for China
Call to Action Global and Regional Hepatitis Action Plans: Opportunities and considerations for China Po-Lin Chan, Senior Advisor Hepatitis/HIV/STI Lan Zhang, Senior Medical Officer Hepatitis/HIV/STI WHO
More informationBio-Rad Laboratories HEMOGLOBIN Testing Bio-Rad A1c. VARIANT II TURBO Link System. Fully-Automated HbA 1c Testing
Bio-Rad Laboratories HEMOGLOBIN Testing Bio-Rad A1c VARIANT II TURBO Link System Fully-Automated HbA 1c Testing Bio-Rad Laboratories HEMOGLOBIN Testing VARIANT II TURBO Link System Efficient streamlined
More informationNew global report highlights silent epidemic of kidney disease and neglect of treatment and prevention in all countries
New global report highlights silent epidemic of kidney disease and neglect of treatment and prevention in all countries An estimated 1 in 10 people worldwide have chronic kidney disease **Embargo: 18:00H
More informationPopulation- based cancer survival estimates
Population- based cancer survival estimates Represent average prognosis of cancer in a specific population Socio-economic features Health care seeking behaviours Coverage and quality of health care services
More informationHCV: how do we reach elimination from a clinicians perspective. A/Professor Gail Matthews
HCV: how do we reach elimination from a clinicians perspective A/Professor Gail Matthews WHO global hepatitis elimination goals by 2030 Elimination a reduction in HCV incidence and HCVrelated mortality
More informationAccess to Care: A Perspective from England. Professor Raman Bedi Chief Dental Officer Department of Health - UK
Access to Care: A Perspective from England Professor Raman Bedi Chief Dental Officer Department of Health - UK Overviews of: NHS System Reform in England Dental Education Developments Oral Health in England
More informationEUROPEAN AEROSOL PRODUCTION
Introduction EUROPEAN AEROSOL PRODUCTION 2017 EU European production Market share Production by segment Worldwide production / FEA, 2018. 1 INTRODUCTION More than 5.7 billion over 16 billion units globally
More informationUtility of Virological Assays at the DAA Era
Utility of Virological Assays at the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationINTRODUCTION TO THE MEDICINES PATENT POOL
www.medspal.org TABLE OF CONTENTS 1. Introduction to the Medicines Patent Pool 2. Background on MedsPaL 3. What patent information is included in MedsPaL? 4. What licensing and data exclusivity information
More informationLessons learned from the IeDEA West Africa Collaboration
Lessons learned from the IeDEA West Africa Collaboration François DABIS with the contribution of Didier Koumavi EKOUEVI INSERM U-897, Bordeaux, France, Programme PACCI, ANRS site, Abidjan, Côte d Ivoire
More informationRecipients of development assistance for health
Chapter 2 Recipients of development assistance for health Both low- and middle-income countries are eligible for development assistance for health (DAH). In addition to income, burden of disease, which
More information